Publications

  1. Kase A, Copland, Tan W. Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate Resistant Prostate Cancer OncoTargets. 2020; 13:10499-10513.
  2. Thong MSY, Chan RJ, van den Hurk C, Fessele K, Tan W, Poprawski D, Fernandez-Ortega P, Paterson C, Fitch MI, MASCC EMA working group. Going beyond (electronic) patient-reported outcomes: harnessing the benefits of smart technology and ecological momentary assessment in cancer survivorship research. Support Care Cancer. 2020 Aug 25 [Epub ahead of print]
    View PubMed
  3. Fettke H, Kwan EM, Docanto MM, Bukczynska P, Ng N, Graham LK, Mahon K, Hauser C, Tan W, Wang XH, Zhao Z, Zheng T, Zhou K, Du P, Yu J, Huang Y, Jia S, Kohli M, Horvath LG, Azad AA. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. Eur Urol. 2020 Aug; 78 (2):173-180 Epub 2020 May 30
    View PubMed
  4. Du M, Huang CC, Tan W, Kohli M, Wang L. Multiplex Digital PCR to Detect Amplifications of Specific Androgen Receptor Loci in Cell-Free DNA for Prognosis of Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2020 Aug 1; 12 (8) Epub 2020 Aug 01
    View PubMed
  5. Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL. Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol. 2020 Jul 20; 38 (21):2438-2453 Epub 2020 May 20
    View PubMed
  6. Tan WW, Windle ML, Braden C, Elston DM. Malignant melanoma Treatment protocols 2020 update Medscape Diagnosis and Disease. 2020.
  7. Abdelhakam D, Young PR, Jain MK, Nassar A, Copland JA, Tan W. Complete remission with immunotherapy: Case report of a patient with metastatic bladder cancer to the humerus. Urol Case Rep. 2020 May; 30:101130 Epub 2020 Feb 12
    View PubMed
  8. Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C, Du P, Jia S, Yadav S, Horvath LG, Mahon KL, Kwan EM, Fettke H, Yu J, Azad AA. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine. 2020 Apr; 54:102728
    View PubMed
  9. Du M, Tian Y, Tan W, Wang L, Wang L, Kilari D, Huang CC, Wang L, Kohli M. Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 Mar 18 [Epub ahead of print]
    View PubMed
  10. Djojat H, Tan WW. Muscle invasive Bladder Cancer: 2020 Multidisciplinary Tumor Board ASCO Univeristy. 2020; 1(1).
  11. Tan W, Windle M , Able J . Prostate Cancer Treatment Protocols Medscape Drugs and Diseases: Reference. 2020.
  12. Tan W, Anand J , Braden CD , Eldelry WS El-Delry WS. Cancer of unknown primary; treatment protocol Medscape; reference disease and diagnosis. 2020.
  13. You B, Mercier F, Assenat E, Langlois-Jacques C, Glehen O, Soule J, Payen L, Kepenekian V, Dupuy M, Belouin F, Morency E, Saywell V, Flaceliere M, Elies P, Liaud P, Mazard T, Maucort-Boulch D, Tan W, Vire B, Villeneuve L, Ychou M, Kohli M, Joubert D, Prieur A. The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine. 2020 Jan; 51:102574 Epub 2019 Dec 24
    View PubMed
  14. Tan WW, Heniford BT, Talavera F, Williams J. Lentigo Maligna: review article Medscape: Drugs and diseases: Oncology. 2019.
  15. Tan W, Karim NA , Anand J . Mesothelioma: staging protocol Medscape WEbMD. 2019. Epub 2019 Nov 02.
  16. Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, Roy V, Vishnu P, Marin-Acevedo J, Alegria VR, Paulus A, Aulakh S, Iqbal M, Manochakian R, Tan W, Chanan-Khan A, Ailawadhi M. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019 Sep 30; 9 (10):75 Epub 2019 Sept 30
    View PubMed
  17. Kesler A, Tan WW, Gabriel E, Kroner PT. A rare Location for a rare Gastrointestinal tumor with a classical presentation of abdominal pain and gastrointestinal bleeding American Journal of Gastroenterology. 2019; 114(S):1386-1387.
  18. Ligibel JA, Jones LW, Brewster AM, Clinton SK, Korde LA, Oeffinger KC, Bender CM, Tan W, Merrill JK, Katta S, Alfano CM. Oncologists' Attitudes and Practice of Addressing Diet, Physical Activity, and Weight Management With Patients With Cancer: Findings of an ASCO Survey of the Oncology Workforce. J Oncol Pract. 2019 Jun; 15 (6):e520-e528 Epub 2019 May 16
    View PubMed
  19. Amar S, Shahab N, Tan W. Metastatic cancer; cancer of unknown primary Medscape: Drugs and diseases; Oncology. 2019.
  20. Stein MN, Chen YH, Carducci MA, Hudes GR, Lerma PM, Tan WW, Dalune R, Rowland KM, Kuzel TM, DiPaola RS. Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805). Am J Clin Oncol. 2019 Apr; 42 (4):375-381
    View PubMed
  21. Jimenez RE, Atwell TD, Sicotte H, Eckloff B, Wang L, Barman P, Sinnwell JP, Eiken PW, McMenomy BP, Tan W, Wang L, Carlson RE, Kohli M. A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens. Mayo Clin Proc Innov Qual Outcomes. 2019 Mar; 3 (1):14-22 Epub 2019 Feb 26
    View PubMed
  22. Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, Tan W, Body JJ, Migliorati C, Lalla RV, MASCC Bone Study Group. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019 Feb; 27 (2):383-394 Epub 2018 Oct 23
    View PubMed
  23. Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018 Sep; 21 (3):431-437 Epub 2018 June 01
    View PubMed
  24. Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2018 Sep; 21 (3):411-418 Epub 2018 June 01
    View PubMed
  25. Chumsri S, Sperinde J, Liu H, Gligorov J, Spano JP, Antoine M, Moreno Aspitia A, Tan W, Winslow J, Petropoulos CJ, Chenna A, Bates M, Weidler JM, Huang W, Dueck A, Perez EA. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res. 2018 Jul 1; 24 (13):3053-3058 Epub 2018 Mar 12
    View PubMed
  26. Kase A, Swaika A, Tan WW. Rare Paraneoplastic Dermatomyositis Secondary to High Grade Bladder Cancer The Journal of Community and Supportive Oncology. 2018.
  27. Kase AM, Menke D, Tan W. Breast cancer metastasis to the bladder: a literature review. BMJ Case Rep. 2018 Jun 28; 2018 Epub 2018 June 28
    View PubMed
  28. Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Res. 2018 Jun 14; 20 (1):52 Epub 2018 June 14
    View PubMed
  29. Windle M, Tan W. Guidelines on radiation and chemotherapy induced Nausea and vomiting Medscape: WebMD diagnosis and diseases. 2018.
  30. Campone M, Laroix-Triki M, Roca L, Spielmann M, Wildiers H, Tan W, Roche H. UCBG 2-08: 5 year efficacy results from the UNICancer-PACS-08 randomized phase III trial of adjucant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer European Journal of Cancer. 2018.
  31. Niazi S, Frank RD, Sharma M, Roy V, Ames S, Rummans T, Spaulding A, Sher T, Ailawadhi M, Bhatia K, Ahmed S, Tan W, Chanan-Khan A, Ailawadhi S. Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. Blood Adv. 2018 May 22; 2 (10):1120-1128
    View PubMed
  32. Blanchard M, Burton MC, Geraci MW, Madaio MP, Marsh JD, Proweller A, Rockey DC, Salata RA, Tan W, Williams CS, Zaidi M, Todd RF 3rd. Best Practices for Physician-Scientist Training Programs: Recommendations from the Alliance for Academic Internal Medicine. Am J Med. 2018 May; 131 (5):578-584 Epub 2018 Feb 02
    View PubMed
  33. Tan W, Windle M, Elston D. Malignant melanoma treatment protocols Medscape Drug and Diseases Reference. March 14, 2018.
  34. Tan , W, Cloutier M . Cancer Survivorship Guidelines : Summary Medscape Drug and Diseases: Guidelines. 2018.
  35. Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018 Feb 1; 29 (2):352-360
    View PubMed
  36. Thomas, L, Harry, E, Quirk, R, Gooding, H, Ripp, J, James, T, Kosub, KY, Pinto-Powell, RC, Orangge, H, Panagiotti, M, Tan, W, Tomescu, O. Evidence-Based Interventions for Medical Student, Trainee and Practicing Physician Wellbeing: A CHARM Annotated Bibliography. Tomescu O, editor Academic Alliance in Medicine.2017;75 p. 111 citations.:
  37. Kohli M, Ho Y, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res. 2017 Aug 15; 23 (16):4704-4715 Epub 2017 May 04
    View PubMed
  38. Yu K, Sang QA, Lung PY, Tan W, Lively T, Sheffield C, Bou-Dargham MJ, Liu JS, Zhang J. Personalized chemotherapy selection for breast cancer using gene expression profiles. Sci Rep. 2017 Mar 3; 7:43294 Epub 2017 Mar 03
    View PubMed
  39. Ho TH, Serie DJ, Parasramka M, Cheville JC, Bot BM, Tan W, Wang L, Joseph RW, Hilton T, Leibovich BC, Parker AS, Eckel-Passow JE. Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. Ann Oncol. 2017 Mar 1; 28 (3):604-610
    View PubMed
  40. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 Sep 10; 34 (26):3119-25 Epub 2016 June 06
    View PubMed
  41. Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Res. 2016 Jul 1; 76 (13):3702-10 Epub 2016 Apr 20
    View PubMed
  42. Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, Morgan SC, Tyldesley S, Haluschak JJ, Tan W, Justman S, Jain S. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016 Jun 20; 34 (18):2182-90 Epub 2016 Feb 16
    View PubMed
  43. Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open. 2016 Apr 15; 6 (4):e010332
    View PubMed
  44. Tan WW, Allred JB, Moreno-Aspitia A, Northfelt DW, Ingle JN, Goetz MP, Perez EA. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. Clin Breast Cancer. 2016 Apr; 16 (2):82-6 Epub 2015 Nov 17
    View PubMed
  45. Tan W, Boorjian S, Advani P, Farmer S, Lohse C, Cheville J, Kwon E, Leibovich B. The Estrogen Pathway: Estrogen Receptor-alpha, Progesterone Receptor, and Estrogen Receptor-beta Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. Clin Genitourin Cancer. 2015 Oct; 13 (5):476-84 Epub 2015 Apr 15
    View PubMed
  46. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67 (1):33-41 Epub 2014 Aug 14
    View PubMed
  47. Copland JA, Marcus J, Wu K, Cernigliaro JG, Tan WW. A patient with metastatic clear cell renal carcinoma with long term survival spanning the era of pre-targeted to molecular targeted treatment. Annals of Hematology & Oncology 4 [Peer-reviewed article]. 2014 Nov; 1(2).
  48. Gardner F, Wu K, Tan WW. Male choriocarcinoma with pulmonary and liver metastases, choriocarcinoma syndrome, and brain metastasis: a case report and review of the literature. Annals of Hematology and Oncology. 2014 Sept 3; 1(1):1-3. Epub 2014 Sep
  49. Gupta E, Guthrie T, Tan W. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol. 2014 Jul 25; 14:55 Epub 2014 July 25
    View PubMed
  50. Ames SC, Pokorny SB, Schroeder DR, Tan W, Werch CE. Integrated smoking cessation and binge drinking intervention for young adults: a pilot efficacy trial. Addict Behav. 2014 May; 39 (5):848-53 Epub 2014 Feb 12
    View PubMed
  51. Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):477-83. Epub 2013 Jul 26.
    View PubMed
  52. Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol. 2013 Oct; 24 (10):2548-2554 Epub 2013 June 24
    View PubMed
  53. Tan WW. Skin lesions caused by Cancer Chemotherapy. Medscape: reference. 09/04/2013; (9):1-16.
  54. von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW, Copland JA. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013 May 1; 19 (9):2368-80 Epub 2013 Apr 30
    View PubMed
  55. Valery JR, Tan W, Cortese C. Renal leiomyosarcoma: a diagnostic challenge. Case Rep Oncol Med. 2013; 2013:459282 Epub 2013 Oct 29
    View PubMed
  56. Gardner FP, Tan WW. Ataxia in a patient with urothelial carcinoma: Pathologic confirmation, recovery, and improved survival. Clin. adv. hematol. oncol. 2013; 11(7):465-7.
  57. Tan WW, Heckman MG, Vishnu P, Crook JE, Younkin LH, Covil EG, Ferman TJ, Graff-Radford NR, Younkin SG, Smallridge RC, Wehle MJ, Buskirk SJ. Effect of leuprolide on serum amyloid-beta peptide levels and memory in patients with prostate cancer with biochemical recurrence. Urology. 2013 Jan; 81: (1)150-4.
    View PubMed
  58. Ahmad A, Wu K, Tan WW. Renal Cell Carcinoma with Skin metastasis: A Case Report and Literature Review. Cancer and Clinical Oncology. 01/2013; 2(1):1-7.
  59. Ahmad A, Tan W. Atypical Presentation of Prostate Cancer and the Workup of an Adenocarcinoma of Unknown Primary. World J Oncol. 2012 Aug; 3 (4):187-190 Epub 2012 Aug 26
    View PubMed
  60. Andhavaradrapu S, Tan WW. Practical insights and challenges in the rational use of targeted agents in metastatic clear cell renal carcinoma. Cancer and Clinical Oncology. 2012 May; 125(1361):102-104 Epub 2012.
  61. Tan WW, Allred JB, Salim M, Flynn P, Fishkin PA, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer. 2012 Apr; 12 (2):81-6
    View PubMed
  62. Finn L, Tan W. Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents. ISRN Oncol. 2012; 2012:478607 Epub 2012 June 03
    View PubMed
  63. Andhavarapu S, Tan WW. Medical image. papules of unknown aetiology. Disseminated Curvularia. N Z Med J. 2012; 125(1361):102-4. Epub 2012 Sep 07.
    View PubMed
  64. Ahmad A, Tan WW. Castrate Resistant Metastatic Prostate Cancer: Options for a Patient in 2012. Open Journal Urology. 2012; 2:210-215 Epub 2012 Oct.
  65. Ames SC, Tan WW, Ames GE, Stone RL, Rizzo TD, Crook JE, Williams CR, Werch CE, Clark MM, Rummans TA. A pilot investigation of a multidisciplinary quality of life intervention for men with biochemical recurrence of prostate cancer. Psychooncology. 2011 Apr; 20(4):435-40. Epub 2010 May 24.
    View PubMed
  66. Ames SC, Parker AS, Crook JE, Diehl NN, Tan WW, Williams CR, Ames GE. Quality of life of patients undergoing surgical treatment for newly-diagnosed, clinically localized renal cell carcinoma. J Psychosoc Oncol. 2011; 29(6):593-605.
    View PubMed
  67. Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther. 2011; 4:97-113 Epub 2011 July 11
    View PubMed
  68. Tzou K, Tan WW, Buskirk S. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy. Expert Rev Anticancer Ther. 2011 Jan; 11(1):125-36.
    View PubMed
  69. Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther. 2010 Jun 24; 3:39-51 Epub 2010 June 24
    View PubMed
  70. Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2010 Mar; 21 (3):493-497 Epub 2009 July 22
    View PubMed
  71. Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, Coppola KE, McLaughlin SA, Palmieri FM, Perez EA. Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist. 2010; 15 (10):1043-9 Epub 2010 Oct 07
    View PubMed
  72. Hines S, Tan WW, Moreno A, Roy V, Vallow L, Mclaughlin S, Perez, E. A practical Clinical approach to Adjuvant Therapy in Breast Cancer- An update. US Oncological Review. 2009; 5 (1):49-53.
  73. Moss JE, Tan WW, Menke DM, Johnson MM. Multiple pulmonary nodules in an asymptomatic man. The Journal of Medicine. 2009; 2(4):205-10.
  74. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7940-6.
    View PubMed
  75. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008 Sep; 19 (9):1561-5 Epub 2008 June 05
    View PubMed
  76. Coe SG, Tan WW, Fox TP. Cushing's syndrome due to ectopic adrenocorticotropic hormone production secondary to hepatic carcinoid: diagnosis, treatment, and improved quality of life. J Gen Intern Med. 2008 Jun; 23 (6):875-8 Epub 2008 Apr 02
    View PubMed
  77. Hines SL, Tan W, Larson JM, Thompson KM, Jorn HK, Files JA. A practical approach to guide clinicians in the evaluation of male patients with breast masses. Geriatrics. 2008 Jun; 63(6):19-24.
    View PubMed
  78. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, Rosser CJ. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 2008; 8:132. Epub 2008 May 11.
    View PubMed
  79. Ames SC, Tan WW, Ames GE, Stone RL, Rizzo TD Jr, Heckman MG, Crook JE, Clark MM, Rummans TA, Werch CE. Quality of life of men with biochemical recurrence of prostate cancer. J Psychosoc Oncol. 2008; 26 (2):17-34
    View PubMed
  80. Tan W. [Promising new treatment options for metastatic androgen-independent prostate cancer]. Actas Urol Esp. 2007 Jun; 31 (6):680-5
    View PubMed
  81. Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis. Mayo Clin Proc 2007 Apr; 82 (4):521
    View PubMed
  82. Hines SL, Tan WW, Yasrebi M, DePeri ER, Perez EA. The role of mammography in male patients with breast symptoms. Mayo Clin Proc. 2007 Mar; 82: (3)297-300.
    View PubMed
  83. Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W, North Central Cancer Treatment Group. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology. 2007 Feb; 69 (2):289-94
    View PubMed
  84. Lee S, Desai KK, Iczkowski KA, Newcomer RG, Wu KJ, Zhao YG, Tan WW, Roycik MD, Sang QX. Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res. 2006 Sep; 16(9):750-8.
    View PubMed
  85. Tan WW. Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control. 2006 Jul; 13 (3):194-8
    View PubMed
  86. Hughes CL, Tan WW, Ferrone M. Sorafenib for the treatment of renal cell carcinoma. J Pharm Technol. 2006; 22(5):281-8.
  87. Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, Erlichman C, Ivy P. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer. 2005 Sep; 4(2):138-41.
    View PubMed
  88. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs. 2005 Jun; 23 (3):257-61
    View PubMed
  89. Baweja M, Tan W. Bone metastases from Prostate cancer: Known and Novel targets for palliation. Palliative and Supportive Cancer care Journal. 2005; 1(2):47-58.
  90. Tan M, Tan W. Polypharmacy in the Elders.(CME article) Federal Practitioner. 2005; 22(11):76-88.
  91. Mincey BA, Tan WW. The management of bone loss in patients with breast or prostate cancer. Support Cancer Ther. 2004 Apr 1; 1 (3):150-6
    View PubMed
  92. Tan M, Tan W. Osteoporosis in prostate cancer(CME Article). Federal Practitioner. 2004; 21(12):72-9.
  93. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. 2003 Mar 15; 97(6):1442-6.
    View PubMed
  94. Tan W, Tan M. Diagnostic Dilemma: Diagnostic test for bifrontal, intractable headache. Hospital Medicine. 1999; 35(8):212-14.
  95. Tan WW, Walsh T. Ocular toxicity secondary to paclitaxel in two lung cancer patients. Medical & Pediatric Oncology. 1998 Sep; 31(3):177.
    View PubMed
  96. Tan W. Malignant mesothelioma. Hospital Medicine. 1998; 34(11):54-6.
  97. Tan W. Diagnostic dilemma-rapidly growing mass (osteogenic sarcoma). Hosp Med.1998;34:(5):40-6.
  98. Tan W, Herzlich BC, Funaro R, Koutelos K, Pagala M, Amaladevi B, Grob D. Rhabdomyolysis and myoglobinuric acute renal failure associated with classic heat stroke. South Med J. 1995 Oct; 88(10):1065-8.
    View PubMed
  99. Tan W, Chapnick E, Abter EIM, et al. Paromomycin associated pancreatitis in HIV related cryptosoridiosis. Ann Pharmacother. 1995; 29:22-3.
    View PubMed
  100. Tan W, Schiano TD, Moss D, Herzlich BC. Hepatic artery aneurysm associated with acute gastroenteritis: successful treatment after intraperitoneal rupture. South Med J. 1994 Aug; 87(8):831-2.
    View PubMed
  101. Tan W, Chua M. Hemolytic anemia in SLE. The Philippine Journal of Pediatrics. 1989; 38(4):255-8.
  102. Tan W, Tiu A, Sy E. Infantile polyarteritis nodosa with gangrene: a case report. The Filipino Family Physician Journal.1987;25:(2):13-5.